Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean E Collins

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
AIDS (London, England)|April 25, 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/IPaul E Sax, Kristen Andreatta, Jean-Michel Molina, et al.
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
AIDS (London, England)|April 25, 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/IPaul E Sax, Kristen Andreatta, Jean-Michel Molina, et al.
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
The Lancet. HIV|June 7, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trialsChloe Orkin, Edwin DeJesus, Paul E Sax, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Lancet (London, England)|July 27, 2020
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialKenneth H Mayer, Jean-Michel Molina, Melanie A Thompson, et al.
The Lancet. HIV|August 29, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trialPatrice Severe, Samuel Pierre, Fabienne Homeus, et al.
Pageof 3